We partner with leading academic cancer research centres which complements our own world-class in-house expertise and laboratory infrastructure and enables us to implement a broader and more effective development strategy


In addition, in line with our strategy we have initiated out-licensing discussions with multiple large biopharmaceutical companies. These licencing discussions are focused on partnerships for: 

  1. the Company’s core cancer therapeutic programs: Midkine antibodies, Midkine RNA therapeutics, STAT-6 siRNA therapeutics and MK cell therapy; and
  2. non-core applications such as diagnostics, biomarker detection and therapy areas outside of cancer.


If you are interested in partnering Roquefort Therapeutics please contact us on



Two jigsaw piece image denoting partnership



Roquefort Therapeutic PLC Logo